source
- Compounders still supply about 20% of US GLP-1 weight-loss market despite FDA crackdown and shortagesA recent Gallup survey shows that while the number of Americans taking GLP-1 weight‑loss drugs has nearly quadrupled over the past two years, roughly one in five are using cheaper, non‑FDA‑approved…
- BlossomHill and Latigo lead a surge of biotech IPOs after summer dry spellAfter a seven‑month lull that left no biotech companies on the public markets last summer, the sector is seeing renewed activity. BlossomHill Therapeutics and Latigo have filed to list on Nasdaq,…